Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Arkansas
M.D. Anderson Cancer Center
Medical College of Wisconsin
University of Alabama at Birmingham
Stichting Hemato-Oncologie voor Volwassenen Nederland
University Hospital, Lille
City of Hope Medical Center
University of Turin, Italy
Thomas Jefferson University
University of Rochester
University of Arkansas
Weill Medical College of Cornell University
Washington University School of Medicine
Janssen Research & Development, LLC
University of Arkansas
University of Arkansas
University of Arkansas
City of Hope Medical Center
City of Hope Medical Center
Thomas Jefferson University
Emory University
Weill Medical College of Cornell University
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
Insel Gruppe AG, University Hospital Bern
Uppsala University
University of Illinois at Chicago
Fondazione EMN Italy Onlus
Fondazione EMN Italy Onlus
Fondazione EMN Italy Onlus
Roswell Park Cancer Institute
CASI Pharmaceuticals (China) Co., Ltd.
University of Leeds
National Heart, Lung, and Blood Institute (NHLBI)
St. Petersburg State Pavlov Medical University
Janssen Research & Development, LLC
Case Comprehensive Cancer Center
University of Nebraska
National Cancer Institute (NCI)
Fred Hutchinson Cancer Center
European Myeloma Network B.V.
Barbara Ann Karmanos Cancer Institute
Washington University School of Medicine
Duke University
Oncotherapeutics